Whereas the inclusions of findings from trials like the DAPA-CKD and DAPA-HF strengthen the argument for the therapeutic benefits of SGLT2 inhibitors in CKD (chronic kidney disease) and HF (heart failure), some meta-analysis and randomized controlled trials are cited, providing a robust evidence base for clinical effects (Table 2). This evidence concerns the gene SLC5A2 and chronic kidney disease.